• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Seysara (sarecycline)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Seysara (sarecycline)

  • Profile

Profile

Contact Information

Contact: Almirall
Website: https://seysara.com/

Currently Enrolling Trials

    Show More

    General Information

    Seysara (sarecycline) is an oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties.

    Seysara is specifically indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. 

    Seysara is supplied as a tablet for oral administration. If there is no improvement after 12 weeks, treatment should be reassessed. Seysara should be taken once daily, with or without food. To reduce the risk of esophageal irritation and ulceration, Seysara should be administered with adequate amounts of fluid. The recommended dose is based on body weight, as follows:

    Body weight Tablet strength
    33 to 54 kg 60 mg tablet
    55 to 84 kg 100 mg tablet
    85 to 136 kg 150 mg tablet

    Mechanism of Action

    Seysara (sarecycline) is an oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties. The mechanism of action of in treating acne vulgaris is not known.

    Side Effects

    The most common adverse reaction associated with the use of Seysara is nausea.

    Clinical Trial Results

    The FDA approval of Seysara was based on two identically-designed, large, multicenter, randomized, double-blind, placebo-controlled, Phase III studies which assessed in a total of 2,002 subjects 9 years of age and older with moderate to severe facial acne vulgaris. Data demonstrated that once-daily sarecycline 1.5 mg/kg significantly improved acne severity based on Investigator's Global Assessment (IGA) success and significantly reduced inflammatory lesion count versus placebo at week 12. Study 1: IGA Success: 21.9% versus 10.5% and Mean absolute reduction in inflammatory lesions: 15.3 versus 10.2. Study 2: IGA Success 22.6% versus 15.3% and Mean absolute reduction in inflammatory lesions: 15.5 versus 11.1. 

    Approval Date: 2018-10-01
    Company Name: Almirall
    Back to Listings

    Upcoming Events

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • tablet

      Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

    • Diversity-360x240.png

      Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing